drugset / Trial / NCT00111891

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

NCT00111891

Phase 2 Completed 575 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.

Timeline

Start
2005-06
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Niacin Small molecule
Subject laropiprant Small molecule

Indications